The Filing Desk

Artivion vs MiMedx Group

Artivion AORT · MiMedx Group MDXG · Health Care Equipment

Artivion reported revenue of $441 million in fiscal 2025, about the same as MiMedx Group's $419 million in fiscal 2025. Artivion's revenue grew 13.6% in its latest year, and MiMedx Group's grew 20.0%. Artivion had an operating margin of 7.7%, against 15.3% at MiMedx Group.

Side by side

ArtivionMiMedx Group
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$441M$419M
Revenue growth13.6%20.0%
Revenue growth a year, last 5 years11.8%11.0%
Gross margin64.4%82.6%
Operating margin7.7%15.3%
Net margin2.2%11.6%
Free cash flow$1M—
Free cash flow margin0.2%—
Return on capital3.9%43.3%
Net debt to EBITDA2.7x−1.9x
Dividends and buybacks$0M$0M
Change in diluted share count13.2%0.5%
Last close$18.53$3.11
P/E at the last close——
Insider trades, last 12 monthssold $14.9 million—
Piotroski F-score7 of 97 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ArtivionMiMedx Group
Operating margin
Percent of revenue
ArtivionMiMedx Group
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ArtivionMiMedx Group

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Artivion and MiMedx Group pages.